Quick Summary:
In an increasingly health-conscious global market, understanding the projected trends in Non-alcoholic Steatohepatitis (NASH) treatment is an absolute necessity. This expansive market is estimated at a whooping US$4.8 Billion in 2022, emphasizing its significance for stakeholders. Gaining substantial insights through our report will undoubtedly equip businesses and executives with the foresight necessary to navigate and capitalize on the estimated exponential growth within the Non-alcoholic Steatohepatitis (NASH) market.
The US and China, two of the world's largest economies, show strong forecasted growth in the NASH market. With the U.S market estimated at $1.6 Billion, and China projected to reach a market size of US$24 Billion by year 2030, proficiency in these market sectors and understanding the potential impact of NASH developments is paramount for any business executive. Our report offers the crucial insights into these markets, and others including Japan, Canada and Germany, reaffirming its worth as an invaluable tool in your strategic planning.
Global Non-alcoholic Steatohepatitis (NASH) Market to Reach $160.7 Billion by 2030
The global market for Non-alcoholic Steatohepatitis (NASH) estimated at US$4.8 Billion in the year 2022, is projected to reach a revised size of US$160.7 Billion by 2030, growing at a CAGR of 55% over the analysis period 2022-2030. Vitamin E & Pioglitazone, one of the segments analyzed in the report, is projected to record 45.7% CAGR and reach US$53.4 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Obeticholic Acid (OCA) segment is readjusted to a revised 43.9% CAGR for the next 8-year period.
The U.S. Market is Estimated at $1.6 Billion, While China is Forecast to Grow at 51.9% CAGR
The Non-alcoholic Steatohepatitis (NASH) market in the U.S. is estimated at US$1.6 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$24 Billion by the year 2030 trailing a CAGR of 51.9% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 46.6% and 45.2% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 35.4% CAGR.Select Competitors (Total 12 Featured) -
- AstraZeneca PLC
- Conatus Pharmaceuticals Inc.
- Galmed Pharmaceuticals Ltd.
- Genfit SA
- Gilead Sciences, Inc.
- Immuron Ltd.
- Intercept Pharmaceuticals, Inc.
- Zydus Cadila
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and the publisher's Research Platform
- Complimentary updates for one year
Frequently Asked Questions about the Global Market for Non-alcoholic Steatohepatitis (NASH)
What is the estimated value of the Global Market for Non-alcoholic Steatohepatitis (NASH)?
The Global Market for Non-alcoholic Steatohepatitis (NASH) was estimated to be valued at $4.8 Billion in 2022.
What is the growth rate of the Global Market for Non-alcoholic Steatohepatitis (NASH)?
The growth rate of the Global Market for Non-alcoholic Steatohepatitis (NASH) is 55.1%, with an estimated value of $160.7 Billion by 2030.
What is the forecasted size of the Global Market for Non-alcoholic Steatohepatitis (NASH)?
The Global Market for Non-alcoholic Steatohepatitis (NASH) is estimated to be worth $160.7 Billion by 2030.
Who are the key companies in the Global Market for Non-alcoholic Steatohepatitis (NASH)?
Key companies in the Global Market for Non-alcoholic Steatohepatitis (NASH) include AstraZeneca PLC, Conatus Pharmaceuticals Inc., Galmed Pharmaceuticals Ltd., Genfit SA, Gilead Sciences, Inc., Immuron Ltd., Intercept Pharmaceuticals, Inc. and Zydus Cadila.
| Report Attribute | Details |
|---|---|
| No. of Pages | 179 |
| Published | October 2023 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 4.8 Billion |
| Forecasted Market Value ( USD | $ 160.7 Billion |
| Compound Annual Growth Rate | 55.1% |
| Regions Covered | Global |
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERSIV. COMPETITION
1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Non-alcoholic Steatohepatitis (NASH) - Global Key Competitors Percentage Market Share in 2022 (E)
- Impact of Covid-19 and a Looming Global Recession
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
4. GLOBAL MARKET PERSPECTIVE
- Table 1: World Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis (NASH) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 2: World Historic Review for Non-alcoholic Steatohepatitis (NASH) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 3: World 16-Year Perspective for Non-alcoholic Steatohepatitis (NASH) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030
- Table 4: World Recent Past, Current & Future Analysis for Vitamin E & Pioglitazone by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 5: World Historic Review for Vitamin E & Pioglitazone by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 6: World 16-Year Perspective for Vitamin E & Pioglitazone by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 7: World Recent Past, Current & Future Analysis for Obeticholic Acid (OCA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 8: World Historic Review for Obeticholic Acid (OCA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 9: World 16-Year Perspective for Obeticholic Acid (OCA) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 10: World Recent Past, Current & Future Analysis for Elafibranor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 11: World Historic Review for Elafibranor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 12: World 16-Year Perspective for Elafibranor by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 13: World Recent Past, Current & Future Analysis for Selonsertib & Cenicriviroc by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 14: World Historic Review for Selonsertib & Cenicriviroc by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 15: World 16-Year Perspective for Selonsertib & Cenicriviroc by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 16: World Recent Past, Current & Future Analysis for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 17: World Historic Review for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 18: World 16-Year Perspective for Hospital Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 19: World Recent Past, Current & Future Analysis for Online Provider by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 20: World Historic Review for Online Provider by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 21: World 16-Year Perspective for Online Provider by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 22: World Recent Past, Current & Future Analysis for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 23: World Historic Review for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 24: World 16-Year Perspective for Retail Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 25: World Non-alcoholic Steatohepatitis (NASH) Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
III. MARKET ANALYSIS
- UNITED STATES
- Non-alcoholic Steatohepatitis (NASH) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
- Table 26: USA Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 27: USA Historic Review for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 28: USA 16-Year Perspective for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Percentage Breakdown of Value Sales for Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc for the Years 2014, 2023 & 2030
- Table 29: USA Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy, Online Provider and Retail Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 30: USA Historic Review for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy, Online Provider and Retail Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 31: USA 16-Year Perspective for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Online Provider and Retail Pharmacy for the Years 2014, 2023 & 2030
- CANADA
- Table 32: Canada Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 33: Canada Historic Review for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 34: Canada 16-Year Perspective for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Percentage Breakdown of Value Sales for Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc for the Years 2014, 2023 & 2030
- Table 35: Canada Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy, Online Provider and Retail Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 36: Canada Historic Review for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy, Online Provider and Retail Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 37: Canada 16-Year Perspective for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Online Provider and Retail Pharmacy for the Years 2014, 2023 & 2030
- JAPAN
- Non-alcoholic Steatohepatitis (NASH) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
- Table 38: Japan Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 39: Japan Historic Review for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 40: Japan 16-Year Perspective for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Percentage Breakdown of Value Sales for Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc for the Years 2014, 2023 & 2030
- Table 41: Japan Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy, Online Provider and Retail Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 42: Japan Historic Review for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy, Online Provider and Retail Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 43: Japan 16-Year Perspective for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Online Provider and Retail Pharmacy for the Years 2014, 2023 & 2030
- CHINA
- Non-alcoholic Steatohepatitis (NASH) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
- Table 44: China Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 45: China Historic Review for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 46: China 16-Year Perspective for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Percentage Breakdown of Value Sales for Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc for the Years 2014, 2023 & 2030
- Table 47: China Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy, Online Provider and Retail Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 48: China Historic Review for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy, Online Provider and Retail Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 49: China 16-Year Perspective for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Online Provider and Retail Pharmacy for the Years 2014, 2023 & 2030
- EUROPE
- Non-alcoholic Steatohepatitis (NASH) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
- Table 50: Europe Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis (NASH) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
- Table 51: Europe Historic Review for Non-alcoholic Steatohepatitis (NASH) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 52: Europe 16-Year Perspective for Non-alcoholic Steatohepatitis (NASH) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030
- Table 53: Europe Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 54: Europe Historic Review for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 55: Europe 16-Year Perspective for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Percentage Breakdown of Value Sales for Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc for the Years 2014, 2023 & 2030
- Table 56: Europe Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy, Online Provider and Retail Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 57: Europe Historic Review for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy, Online Provider and Retail Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 58: Europe 16-Year Perspective for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Online Provider and Retail Pharmacy for the Years 2014, 2023 & 2030
- FRANCE
- Non-alcoholic Steatohepatitis (NASH) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
- Table 59: France Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 60: France Historic Review for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 61: France 16-Year Perspective for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Percentage Breakdown of Value Sales for Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc for the Years 2014, 2023 & 2030
- Table 62: France Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy, Online Provider and Retail Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 63: France Historic Review for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy, Online Provider and Retail Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 64: France 16-Year Perspective for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Online Provider and Retail Pharmacy for the Years 2014, 2023 & 2030
- GERMANY
- Non-alcoholic Steatohepatitis (NASH) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
- Table 65: Germany Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 66: Germany Historic Review for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 67: Germany 16-Year Perspective for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Percentage Breakdown of Value Sales for Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc for the Years 2014, 2023 & 2030
- Table 68: Germany Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy, Online Provider and Retail Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 69: Germany Historic Review for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy, Online Provider and Retail Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 70: Germany 16-Year Perspective for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Online Provider and Retail Pharmacy for the Years 2014, 2023 & 2030
- ITALY
- Table 71: Italy Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 72: Italy Historic Review for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 73: Italy 16-Year Perspective for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Percentage Breakdown of Value Sales for Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc for the Years 2014, 2023 & 2030
- Table 74: Italy Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy, Online Provider and Retail Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 75: Italy Historic Review for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy, Online Provider and Retail Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 76: Italy 16-Year Perspective for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Online Provider and Retail Pharmacy for the Years 2014, 2023 & 2030
- UNITED KINGDOM
- Non-alcoholic Steatohepatitis (NASH) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
- Table 77: UK Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 78: UK Historic Review for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 79: UK 16-Year Perspective for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Percentage Breakdown of Value Sales for Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc for the Years 2014, 2023 & 2030
- Table 80: UK Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy, Online Provider and Retail Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 81: UK Historic Review for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy, Online Provider and Retail Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 82: UK 16-Year Perspective for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Online Provider and Retail Pharmacy for the Years 2014, 2023 & 2030
- REST OF EUROPE
- Table 83: Rest of Europe Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 84: Rest of Europe Historic Review for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 85: Rest of Europe 16-Year Perspective for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Percentage Breakdown of Value Sales for Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc for the Years 2014, 2023 & 2030
- Table 86: Rest of Europe Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy, Online Provider and Retail Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 87: Rest of Europe Historic Review for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy, Online Provider and Retail Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 88: Rest of Europe 16-Year Perspective for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Online Provider and Retail Pharmacy for the Years 2014, 2023 & 2030
- ASIA-PACIFIC
- Non-alcoholic Steatohepatitis (NASH) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
- Table 89: Asia-Pacific Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 90: Asia-Pacific Historic Review for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 91: Asia-Pacific 16-Year Perspective for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Percentage Breakdown of Value Sales for Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc for the Years 2014, 2023 & 2030
- Table 92: Asia-Pacific Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy, Online Provider and Retail Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 93: Asia-Pacific Historic Review for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy, Online Provider and Retail Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 94: Asia-Pacific 16-Year Perspective for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Online Provider and Retail Pharmacy for the Years 2014, 2023 & 2030
- REST OF WORLD
- Table 95: Rest of World Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 96: Rest of World Historic Review for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 97: Rest of World 16-Year Perspective for Non-alcoholic Steatohepatitis (NASH) by Drug Type - Percentage Breakdown of Value Sales for Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc for the Years 2014, 2023 & 2030
- Table 98: Rest of World Recent Past, Current & Future Analysis for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy, Online Provider and Retail Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
- Table 99: Rest of World Historic Review for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy, Online Provider and Retail Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
- Table 100: Rest of World 16-Year Perspective for Non-alcoholic Steatohepatitis (NASH) by Sales Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Online Provider and Retail Pharmacy for the Years 2014, 2023 & 2030
Companies Mentioned
A selection of companies mentioned in this report includes:
- AstraZeneca PLC
- Conatus Pharmaceuticals Inc.
- Galmed Pharmaceuticals Ltd.
- Genfit SA
- Gilead Sciences, Inc.
- Immuron Ltd.
- Intercept Pharmaceuticals, Inc.
- Zydus Cadila
